330 related articles for article (PubMed ID: 24985072)
1. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
Jovanović B; Beeler JS; Pickup MW; Chytil A; Gorska AE; Ashby WJ; Lehmann BD; Zijlstra A; Pietenpol JA; Moses HL
Breast Cancer Res; 2014 Jul; 16(4):R69. PubMed ID: 24985072
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
Criswell TL; Dumont N; Barnett JV; Arteaga CL
Cancer Res; 2008 Sep; 68(18):7304-12. PubMed ID: 18794117
[TBL] [Abstract][Full Text] [Related]
3. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
4. COL8A1 enhances the invasion/metastasis in MDA-MB-231 cells via the induction of IL1B and MMP1 expression.
Sagara A; Miura S; Kobinata A; Naganawa R; Yaginuma S; Saito S; Saito R; Kominato H; Yumoto T; Sato F
Biochem Biophys Res Commun; 2023 Jan; 642():145-153. PubMed ID: 36577251
[TBL] [Abstract][Full Text] [Related]
5. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC
Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
[TBL] [Abstract][Full Text] [Related]
6. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.
Hempel N; How T; Cooper SJ; Green TR; Dong M; Copland JA; Wood CG; Blobe GC
Carcinogenesis; 2008 May; 29(5):905-12. PubMed ID: 18299279
[TBL] [Abstract][Full Text] [Related]
7. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.
Elderbroom JL; Huang JJ; Gatza CE; Chen J; How T; Starr M; Nixon AB; Blobe GC
Mol Biol Cell; 2014 Aug; 25(16):2320-32. PubMed ID: 24966170
[TBL] [Abstract][Full Text] [Related]
8. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.
You HJ; How T; Blobe GC
Carcinogenesis; 2009 Aug; 30(8):1281-7. PubMed ID: 19325136
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.
Zhang S; Sun WY; Wu JJ; Gu YJ; Wei W
Oncol Rep; 2016 Apr; 35(4):2373-81. PubMed ID: 26882862
[TBL] [Abstract][Full Text] [Related]
10. A tumor-promoting role for soluble TβRIII in glioblastoma.
Burghardt I; Schroeder JJ; Weiss T; Gramatzki D; Weller M
Mol Cell Biochem; 2021 Aug; 476(8):2963-2973. PubMed ID: 33772427
[TBL] [Abstract][Full Text] [Related]
11. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
Lee JD; Hempel N; Lee NY; Blobe GC
Carcinogenesis; 2010 Feb; 31(2):175-83. PubMed ID: 19955393
[TBL] [Abstract][Full Text] [Related]
12. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
13. The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.
Gatza CE; Elderbroom JL; Oh SY; Starr MD; Nixon AB; Blobe GC
Neoplasia; 2014 Jun; 16(6):489-500. PubMed ID: 25077702
[TBL] [Abstract][Full Text] [Related]
14. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
15. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
[TBL] [Abstract][Full Text] [Related]
16. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
18. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility.
Criswell TL; Arteaga CL
J Biol Chem; 2007 Nov; 282(44):32491-500. PubMed ID: 17823118
[TBL] [Abstract][Full Text] [Related]
19. The type III TGF-beta receptor suppresses breast cancer progression.
Dong M; How T; Kirkbride KC; Gordon KJ; Lee JD; Hempel N; Kelly P; Moeller BJ; Marks JR; Blobe GC
J Clin Invest; 2007 Jan; 117(1):206-17. PubMed ID: 17160136
[TBL] [Abstract][Full Text] [Related]
20. CCN6 knockdown disrupts acinar organization of breast cells in three-dimensional cultures through up-regulation of type III TGF-β receptor.
Pal A; Huang W; Toy KA; Kleer CG
Neoplasia; 2012 Nov; 14(11):1067-74. PubMed ID: 23226100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
